Sanofi’s mRNA Chlamydia Vaccine Gains FDA Fast Track Designation

French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving fast track designation from the US Food and Drug Administration (FDA) for its mRNA vaccine candidate targeting the prevention of chlamydia infection. This designation represents a significant step forward in the development of the vaccine, which is designed to address a common sexually transmitted infection.

Vaccine Development and Trial Plans
The vaccine is formulated to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. Sanofi plans to evaluate its immunogenicity and safety in adults aged 18 to 29 through an imminent Phase I/II randomized study. This trial will provide crucial data on the vaccine’s potential effectiveness and safety profile in the target population.-Fineline Info & Tech